U.S. News hospital rankings delayed due to data errors

The annual hospital rankings from U.S. News and World Report will now be released a week later than scheduled after errors were discovered in data which affected 12 “data-driven specialty rankings.”

This data had already been used in the rankings released to hospitals on July 11. A public release had been scheduled on August 1, but that’s now been pushed back to August 8 to give U.S. News time to review the data and release corrected rankings to hospitals first.

“While these changes … allow us to better assess hospital care, they are complex to implement and we discovered errors late in the process,” U.S. News said in an email, which was sent to participating hospitals and obtained by STAT News. “We are confident that once correctly implemented these changes will benefit our shared goal of providing patients with better information about their health care.”

Methodology behind this year’s rankings has been revised to better for the socioeconomic status of patients served by a hospital, as well as evaluating “the care of low-income patients, patient safety and hospitals that accept very sick patients from other hospitals.” U.S. News didn’t say whether those changes caused any of the data errors which led to the delay.

In the 2016 report, Mayo Clinic topped the rankings, taking the top spot from Boston’s Massachusetts General Hospital.

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.